98 related articles for article (PubMed ID: 26752566)
21. Apolipoprotein E genotyping in Alzheimer's disease. The UK Alzheimer's Disease Genetic consortium.
Lovestone S; Wilcock G; Rossor M; Cayton H; Ragan I
Lancet; 1996 Jun; 347(9017):1775-6. PubMed ID: 8656944
[No Abstract] [Full Text] [Related]
22. [Molecular genetics of Alzheimer's disease].
Akinori M; Ryozo K
Tanpakushitsu Kakusan Koso; 2005 Dec; 50(16 Suppl):2122-7. PubMed ID: 16411440
[No Abstract] [Full Text] [Related]
23. The law, adolescents, and the APOE epsilon 4 genotype: a view from Canada.
Caulfield TA
Genet Test; 1999; 3(1):107-13. PubMed ID: 10464584
[TBL] [Abstract][Full Text] [Related]
24. Changes to perceptions of the pros and cons of genetic susceptibility testing after APOE genotyping for Alzheimer disease risk.
Christensen KD; Roberts JS; Uhlmann WR; Green RC
Genet Med; 2011 May; 13(5):409-14. PubMed ID: 21270636
[TBL] [Abstract][Full Text] [Related]
25. Disclosure of the genetic risk of Alzheimer's disease.
Gordon SC; Landa D
N Engl J Med; 2010 Jan; 362(2):181-2; author reply 182. PubMed ID: 20071713
[No Abstract] [Full Text] [Related]
26. Susceptibility testing for children.
Health Prog; 2003; 84(3):11-2, 50. PubMed ID: 12789851
[No Abstract] [Full Text] [Related]
27. Genetic testing and Alzheimer disease: has the time come? Alzheimer Disease Working Group of the Stanford Program in Genomics, Ethics & Society.
McConnell LM; Koenig BA; Greely HT; Raffin TA
Nat Med; 1998 Jul; 4(7):757-9. PubMed ID: 9662356
[No Abstract] [Full Text] [Related]
28. I Had Genetic Testing for Alzheimer's Disease Without My Consent.
Lucassen A
Narrat Inq Bioeth; 2015; 5(3):214-6. PubMed ID: 26752571
[No Abstract] [Full Text] [Related]
29. Apolipoprotein E Genotyping in Alzheimer's Disease. Chicago, Illinois, October 21-22, 1995. Proceedings.
Ann N Y Acad Sci; 1996 Dec; 802():1-224. PubMed ID: 9012314
[No Abstract] [Full Text] [Related]
30. Apolipoprotein E genotyping in Alzheimer's disease.
Humphries S; Betteridge DJ; Durrington PN; Galton DJ; Nicholls P
Lancet; 1996 Jun; 347(9017):1776. PubMed ID: 8656945
[No Abstract] [Full Text] [Related]
31. Statement on use of apolipoprotein E testing for Alzheimer disease. American College of Medical Genetics/American Society of Human Genetics Working Group on ApoE and Alzheimer disease.
JAMA; 1995 Nov 22-29; 274(20):1627-9. PubMed ID: 7474250
[TBL] [Abstract][Full Text] [Related]
32. [Genetics of Alzheimer's disease].
Hiltunen M; Helisalmi S; Kivipelto M; Soininen H
Duodecim; 2004; 120(20):2425-31. PubMed ID: 15641511
[No Abstract] [Full Text] [Related]
33. To know or not to know: an update of the literature on the psychological and behavioral impact of genetic testing for Alzheimer disease risk.
Rahman B; Meiser B; Sachdev P; Barlow-Stewart K; Otlowski M; Zilliacus E; Schofield P
Genet Test Mol Biomarkers; 2012 Aug; 16(8):935-42. PubMed ID: 22731638
[TBL] [Abstract][Full Text] [Related]
34. Prefrontal activation patterns in subjects at risk for Alzheimer disease.
Petrella JR; Lustig C; Bucher LA; Jha AP; Doraiswamy PM
Am J Geriatr Psychiatry; 2002; 10(1):112-3. PubMed ID: 11790642
[No Abstract] [Full Text] [Related]
35. Genetic testing for everyone.
Pearson H
Nature; 2008 May; 453(7195):570-1. PubMed ID: 18509402
[No Abstract] [Full Text] [Related]
36. Reaching the limits of genome-wide significance in Alzheimer disease: back to the environment.
Pedersen NL
JAMA; 2010 May; 303(18):1864-5. PubMed ID: 20460629
[No Abstract] [Full Text] [Related]
37. [Genetic aspects of Alzheimer disease].
Øksengård AR; Engedal K
Tidsskr Nor Laegeforen; 2002 Feb; 122(5):530-1. PubMed ID: 11961985
[TBL] [Abstract][Full Text] [Related]
38. [Apolipoprotein E and Alzheimer disease].
Berr C
Rev Neurol (Paris); 1995 Jan; 151(1):3-5. PubMed ID: 7676127
[No Abstract] [Full Text] [Related]
39. Bleomycin hydrolase is associated with risk of sporadic Alzheimer's disease.
Montoya SE; Aston CE; DeKosky ST; Kamboh MI; Lazo JS; Ferrell RE
Nat Genet; 1998 Mar; 18(3):211-2. PubMed ID: 9500538
[No Abstract] [Full Text] [Related]
40. Genetic susceptibility testing for Alzheimer disease: motivation to obtain information and control as precursors to coping with increased risk.
Gooding HC; Linnenbringer EL; Burack J; Roberts JS; Green RC; Biesecker BB
Patient Educ Couns; 2006 Dec; 64(1-3):259-67. PubMed ID: 16860524
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
